NIS 20.8m. in R&D projects approved

The Industry, Trade and Labor Ministry's research committee, headed by Chief Scientist Eli Ofer, approved eight research and development programs, bringing investments to NIS 20.8 million in total, the ministry said Tuesday.

By DANIEL KENNEMER
February 1, 2006 07:09

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

The Industry, Trade and Labor Ministry's research committee, headed by Chief Scientist Eli Ofer, approved eight research and development programs, bringing investments to NIS 20.8 million in total, the ministry said Tuesday. Of the total, two were approved in electronics, matching NIS 2.3m. in state grants with NIS 4.3m. of self-funding; three were approved in programming, in which a grant of NIS 2.5m. enabled a total of NIS 6.2m. to be invested; and three more were approved in the fields of medical equipment, plastics, and miscellaneous, granting NIS 3.3m for a total investment of NIS 8m.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS